ClinicalTrials.gg
CompletedNCT04959890Updated Nov 17, 2026Results posted

Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy

An observational study in Severe Combined Immunodeficiency Due to ADA Deficiency, sponsored by Fondazione Telethon. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Fondazione Telethon · Observational

How we know

Updated Nov 17, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
23
Sex
All
01

Study summary

This study is a Post-Authorization Measure to evaluate the accuracy and precision of retroviral insertion site (RIS) analysis and its utility for investigating and predicting the potential for insertional oncogenesis in subjects treated with Strimvelis.

Read the detailed description

This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with Strimvelis. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal.

The objective of this methodology study is to evaluate the accuracy and precision of Sonication and Linker Mediated (SLiM) - PCR for RIS analysis and its utility for investigating and predicting the potential for insertional oncogenesis in subjects previously treated with Strimvelis for severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency.

02

Conditions studied

  • Severe Combined Immunodeficiency Due to ADA Deficiency

Keywords

  • ada-scid
  • retroviral vector
  • gene therapy
03

In context

Severe combined immunodeficiency due to adenosine deaminase deficiency

29 studies on the registry are indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency; 4 are open to participants now.

This study's enrollment of 23 is below the median of 76 across 13 observational studies indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency.

Browse Severe combined immunodeficiency due to adenosine deaminase deficiency studies →

Lead sponsor

Fondazione Telethon is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will use biological samples previously taken from subjects treated with Strimvelis gRV-GT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must have previously received treatment with gRV-GT, either during clinical development (clinical trials and early access programs) or in the post-marketing setting as the approved product (Strimvelis) or under hospital exemption, and for whom at least one biological sample is available that meets the following eligibility criteria:

  1. Peripheral blood, bone marrow, or DNA extracted from either source.
  2. Taken at least 6 months after gRV-GT.
  3. Stored at -20°C or below since the time of sampling.
  4. Likely to provide 500 ng (maximum)of DNA (following extraction by the central laboratory).

Exclusion criteria

Exclusion Criteria N/A

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
23 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects Previously Treated with Strimvelis (or GSK2696273) Gene Therapy

    Subjects who have previously received treatment with gRV-GT, either during clinical development (clinical trials and early access programs) or in the post-marketing setting as the approved product (Strimvelis) or under hospital exemption, and for whom at least one biological sample is available that meets the following eligibility criteria: * Peripheral blood, bone marrow, or DNA extracted from either source. * Taken at least 6 months after gRV-GT. * Stored at -20°C or below since the time of sampling. * Likely to provide 500 ng (maximum)of DNA (following extraction by the central laboratory).

06

What researchers measure

Primary outcomes

  1. Precision of SLiM-PCR Methodology for RIS Analysis Using Control Insertion Site DNA

    Precision was measured as the percentage coefficient of variation (%CV) of the abundance.

    Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day

  2. Accuracy of SLiM-PCR Methodology for RIS Using Control Insertion Site DNA

    Accuracy was determined based on the difference between the mean retrieved abundance and the expected abundance of control DNA.

    Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day

Secondary outcomes

  1. Abundance of Insertion Sites in Subjects Treated With gRV-GT

    Abundance was quantified by listing the top 10 most abundant clones for each sample, including the name of the targeted gene. The number of non-redundant IS retrieved was reported for the whole sample (Unique IS).

    Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day

  2. Diversity of Insertion Sites in Subjects Treated With gRV-GT

    In terms of diversity of insertion sites, a total of 35,587 unique IS were identified across 16 patients and 70 samples (27 BM and 43 mPB).

    Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day

07

Results

Posted Nov 17, 2026
Limitations and caveats
The retrospective nature of the study has benefit in terms of not requiring additional samples from subjects, but as the samples are limited to those that were already in storage, there were limitations related to the number of subjects with samples, the number of samples per subject and the timing of the samples relative to gRV-GT.

Participant flow

Participant flow — Overall Study
MilestoneSubjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Started23
Completed17
Not completed6

Outcome measures

PrimaryPrecision of SLiM-PCR Methodology for RIS Analysis Using Control Insertion Site DNA

Precision was measured as the percentage coefficient of variation (%CV) of the abundance.

Time frame:
Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Reported as:
Number · % relative abundance
Precision of SLiM-PCR Methodology for RIS Analysis Using Control Insertion Site DNA
% relative abundanceSubjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Precision of SLiM-PCR Methodology for RIS Analysis Using Control Insertion Site DNA0.1
PrimaryAccuracy of SLiM-PCR Methodology for RIS Using Control Insertion Site DNA

Accuracy was determined based on the difference between the mean retrieved abundance and the expected abundance of control DNA.

Time frame:
Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Reported as:
Mean · fold change
Accuracy of SLiM-PCR Methodology for RIS Using Control Insertion Site DNA
fold changeSubjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Accuracy of SLiM-PCR Methodology for RIS Using Control Insertion Site DNA1.5 ± 0.27
SecondaryAbundance of Insertion Sites in Subjects Treated With gRV-GT

Abundance was quantified by listing the top 10 most abundant clones for each sample, including the name of the targeted gene. The number of non-redundant IS retrieved was reported for the whole sample (Unique IS).

Time frame:
Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Reported as:
Number · total unique IS
Abundance of Insertion Sites in Subjects Treated With gRV-GT
total unique ISSubjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Abundance of Insertion Sites in Subjects Treated With gRV-GT35587 (187 to 9146)
SecondaryDiversity of Insertion Sites in Subjects Treated With gRV-GT

In terms of diversity of insertion sites, a total of 35,587 unique IS were identified across 16 patients and 70 samples (27 BM and 43 mPB).

Time frame:
Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Reported as:
Mean · number of IS per patient
Diversity of Insertion Sites in Subjects Treated With gRV-GT
number of IS per patientSubjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Diversity of Insertion Sites in Subjects Treated With gRV-GT2224 (187 to 9146)

Adverse events

Collected over Not applicable/collected for this retrospective methodology study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy———

Baseline characteristics

Samples from 17 patients were included in the analysis: samples from 2 patients were used for the primary objective, and samples from 16 patients were used for the secondary objective, with one patient contributing to both analyses. To assess the accuracy and precision of SLiM-PCR, two samples were used.

Age, Continuous
Age, Continuous(years)Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Mean5.54 ± 4.07
Sex: Female, Male
Sex: Female, Male(Participants)Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Female9
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy
Hispanic or Latino2
Not Hispanic or Latino15
Unknown or Not Reported0
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Feb 2024, 33 months.

Results were first posted in Nov 2026, 2 years 9 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Mar 2024 → Feb 2024 and completion Mar 2024 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jul 13, 2021
StartActual
Apr 23, 2021
Primary completionActual
Feb 16, 2024was Mar 2024
CompletionActual
Jun 16, 2025was Mar 2024
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 17, 2026
Results
Results posted
posted Nov 17, 2026
Primary completion
Mar 31, 2024→Feb 16, 2024 (actual)
Nov 17, 2026
Study completion
Mar 31, 2024→Jun 16, 2025 (actual)
Nov 17, 2026
Enrollment
15 (estimated)→23 (actual)
Nov 17, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedStored at -20oC20°C or below since the time of sampling.
  • EditedLikely to provide at least 1.5 μg 500 ng (maximum)of DNA (following extraction by the central laboratory).
Nov 17, 2026
Interventions
Arms or interventions changed
Nov 17, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedTo assess the precisionPrecision of S-EPTS/LMSLiM-PCR methodologyMethodology for RIS analysis using control insertion siteAnalysis Using Control Insertion Site DNATime frame: Retrospective sample analysis. → Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
  • EditedTo assess the accuracyAccuracy of S-EPTS/LMSLiM-PCR methodologyMethodology for RIS using control insertion siteUsing Control Insertion Site DNATime frame: Retrospective sample analysis. → Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Nov 17, 2026
Documents
Secondary outcomes
2 added
What changed in the outcomes
  • AddedAbundance of Insertion Sites in Subjects Treated With gRV-GTTime frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
  • AddedDiversity of Insertion Sites in Subjects Treated With gRV-GTTime frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Mar 31, 2024→Feb 16, 2024 (now actual)
    Study completion Mar 31, 2024→Jun 16, 2025 (now actual)
    Enrollment 15 (estimated)→23 (actual)
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedStored at -20oC20°C or below since the time of sampling.
    • EditedLikely to provide at least 1.5 μg 500 ng (maximum)of DNA (following extraction by the central laboratory).
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedTo assess the precisionPrecision of S-EPTS/LMSLiM-PCR methodologyMethodology for RIS analysis using control insertion siteAnalysis Using Control Insertion Site DNATime frame: Retrospective sample analysis. → Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
    • EditedTo assess the accuracyAccuracy of S-EPTS/LMSLiM-PCR methodologyMethodology for RIS using control insertion siteUsing Control Insertion Site DNATime frame: Retrospective sample analysis. → Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedAbundance of Insertion Sites in Subjects Treated With gRV-GTTime frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
    • AddedDiversity of Insertion Sites in Subjects Treated With gRV-GTTime frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
    Interventions Arms or interventions changed
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04959890
Lead sponsor
Fondazione Telethon
Responsible party
Sponsor
First posted
Jul 13, 2021
Start date
Apr 23, 2021
Primary completion
Feb 16, 2024
Completion
Jun 16, 2025
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Fondazione Telethon
study director · Fondazione Telethon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion